Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 1 Completed 18 enrolled Koen van Besien

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if the study drug, called Vactosertib, is safe and determine what the best dose is to treat future patients when given in combination with pomalidomide (POM). The study will also look to see if it has any effect on multiple myeloma, when given in combination with POM.

Timeline

Start: 2017-07-21
Primary completion: 2022-02-27
Completion: 2022-09-01

Publications

Malek E, Rana PS, Swamydas M, Daunov M, Miyagi M, Murphy E, Ignatz-Hoover JJ, Metheny L, Kim SJ, Driscoll JJ. The TGFbeta type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial. Nat Commun. 2024 Aug 27;15(1):7388. doi: 10.1038/s41467-024-51442-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vactosertib	Small molecule	60 mg	Oral
Subject	Vactosertib	Small molecule	100 mg	Oral
Subject	Vactosertib	Small molecule	120 mg	Oral
Subject	Vactosertib	Small molecule	200 mg	Oral
Subject	Vactosertib	Small molecule	240 mg	Oral
Background	Pomalidomide	Other / unclassified	4 mg	Oral

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications